Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.74
- Piotroski Score 4.00
- Grade Buy
- Symbol (RYTM)
- Company Rhythm Pharmaceuticals, Inc.
- Price $56.25
- Changes Percentage (6.15%)
- Change $3.26
- Day Low $52.46
- Day High $56.56
- Year High $56.56
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $55.00
- High Stock Price Target $64.00
- Low Stock Price Target $25.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.63
- Trailing P/E Ratio -8.63
- Forward P/E Ratio -8.63
- P/E Growth -8.63
- Net Income $-184,678,000
Income Statement
Quarterly
Annual
Latest News of RYTM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish
The US Federal Reserve cutting cycle signals a new investment era amid record-high stock indices. Concerns about a slowing economy prompt interest rate cuts, impacting consumer purchasing power and va...
By Yahoo! Finance | 1 month ago -
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo Finance
Rhythm Pharmaceuticals' application for expanding the use of IMCIVREE (setmelanotide) to treat children as young as 2 with Bardet-Biedl syndrome or POMC/LEPR deficiency has been accepted for priority ...
By Yahoo! Finance | 2 months ago
